Back to today’s briefing

Story perspectives

New CAR-T Therapy Offers Safer Autoimmune Disease Treatment

2/6/2026

50 4

Summary

Story summary

CART4-34 CAR-T therapy targets B cell receptors bearing the IGHV4-34 gene while sparing healthy cells.
It matches the effectiveness of traditional CD19 CAR-T therapy while avoiding immune suppression.
CD19 CAR-T therapy can lead to infections after treatment, whereas CART4-34 may offer a safer alternative.
These engineered T cells could potentially treat autoimmune diseases like lupus, where IGHV4-34 antibodies are prevalent.

1 of 1

Story summary

CART4-34 CAR-T therapy targets B cell receptors bearing the IGHV4-34 gene while sparing healthy cells.
It matches the effectiveness of traditional CD19 CAR-T therapy while avoiding immune suppression.
CD19 CAR-T therapy can lead to infections after treatment, whereas CART4-34 may offer a safer alternative.
These engineered T cells could potentially treat autoimmune diseases like lupus, where IGHV4-34 antibodies are prevalent.